Share on StockTwits

Gilead Sciences (NASDAQ:GILD) EVP Gregg H. Alton sold 33,000 shares of the stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $91.62, for a total transaction of $3,023,460.00. Following the completion of the sale, the executive vice president now directly owns 124,694 shares of the company’s stock, valued at approximately $11,424,464. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.47% during mid-day trading on Tuesday, hitting $91.75. 8,068,701 shares of the company’s stock traded hands. Gilead Sciences has a 52 week low of $55.96 and a 52 week high of $94.34. The stock has a 50-day moving average of $86. and a 200-day moving average of $80.3. The company has a market cap of $140.0 billion and a P/E ratio of 20.88.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $7.91 earnings per share for the current fiscal year.

GILD has been the subject of a number of recent research reports. Analysts at Maxim Group raised their price target on shares of Gilead Sciences from $112.00 to $127.00 in a research note on Monday, July 28th. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 24th. They now have a $110.00 price target on the stock, up previously from $100.00. Finally, analysts at Piper Jaffray raised their price target on shares of Gilead Sciences to $111.00 in a research note on Thursday, July 24th. One equities research analyst has rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $101.63.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.